








Abbreviations. 95%CI: 95% confidence interval; n: number; NA: not applicable; Hgb: haemo-
globin; RBC: red blood cell; +: active treatment; -: no treatment
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Genotype and Phenotype Analysis of Thiopurine-Methyl-Transferase (TPMT)
in a Northern Italian Population
Marco Daperno, Roberto Canaparo, Raffaello Sostegni, Annalisa Vernetto, Loredana Serpe,
Pier L. Calvo, Sergio D'Antico, Lucia Crocellà, Franco Castagno, Angelo Pera, Gian Paolo
Zara, Rodolfo Rocca
Background. Immunomodulators, mainly thiopurines, are increasingly prescribed in inflam-
matory bowel disease (IBD). Thiopurine-methyl-transferase (TPMT) genotype and phenotype
is expected to exhert notable effects on availability and toxicity of these drugs. Aims. To
analyse TPMT genotype and phenotype in a Northern Italian population of healthy controls
and IBD patients. Patients & methods. All consecutive IBD out-patients (n=169) and 533
healthy controls (HC) were recruited. A blood sample was drawn, DNA was extracted and
erytrocytes were separated. Major TPMT genetic variants (TPMT*2, *3A, *3B, *3C) were
analysed by means of PCR techniques, while intra-erythrocyte TMPT activity was analysed
using a standardised high pressure liquid chromatography (HPLC) technique. Clinical data
were recorded. Results. Regarding TPMT genotype, TPMT was mutated in 8/169 (4.7%;
95%CI 1.5-8%) IBD cases (7 heterozigous for *3A and 1 for *3C) and in 34/533 (6.4%;
95%CI 4-8%) HC (28 heterozigous for *3A, 3 for *3B and 3 for *3C); the difference was
not statistically significant (p=0.549). Hardy Weinberg distribution was respected, no mutant
homozygous was observed among cases or controls. No significant differences were noted
in subgroup analysis. As for TPMT activity, the distribution of TPMT activity was sharply
different in IBD cases, with distribution not-normal (p<0.001) and significantly lower than
among HC (however not-normally distributed, p=0.014). TPMT activity figures are reported
in Table. No significant TPMT phenotype difference was noted according to IBD subgroups
based on TPMT genotype or on clinical characteristic. We found only that IBD patients on
systemic steroids (n=16) had higher median TPMT activity (46.54 nmol/h/g Hgb) compared
to those not on steroid treatment (n=153, 26.98 nmol/h/g Hgb), p=0.0023. Discussion.
This is the first report on TPMT genotypic and phenotypic characteristics in a Northern
Italian population. No difference was observed for TPMT genotype comparing cases and
controls, however allelic frequency was lower than expected and no homozygous mutant
subject was observed. TPMT activity was lower in IBD patients compared to healthy controls.
Larger groups of patients are under investigation in order to confirm observations.
Abbreviations. IQR: interquartile range; p: p-value; HC: healthy controls
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Which 5-ASA? Variation in Colonic Mucosal Concentration of Different
Pharmaceutical mesalamine Formulations
Renata D'Incà, Martina Paccagnella, Romilda Cardin, Sandra Voltan, Vincenzo Baldo,
Giacomo C. Sturniolo
Aim: 5-Aminosalicylic acid (5-ASA or mesalamine) represents the mainstay treatment of
inflammatory bowel disease (IBD): different pharmaceutical formulations have been
developed in order to obtain absorption at the site of the disease. Our aim was to evaluate
the mucosal concentration of each formulation. Patients and methods: 130 consecutive IBD
patients receiving oral 5-ASA either pH-dependent release formulations (2.4 g/day) (73
patients), time-dependent release formulations (3 g/day) (11 patients) or pro-drugs (3 g/
day) (18 patients), were included in the study. 28 patients received both oral and topical
(2-4 g/day enema) of pH-dependent release formulation. Two endoscopic biopsies were
taken from the sigmoid colon in each patient undergoing colonoscopy for surveillance
or symptom reexacerbation. Mesalamine concentration (ng/mg) was measured in tissue
homogenates by high-pressure liquid chromatographywith electrochemical detection. Endos-
copic and histological disease activity were recorded as remission or active disease. The T-
test and Mann-Whitney's test were used for statistical analysis. Results: pH-dependent release
formulations achieved higher mucosal concentrations than prodrugs (51.75±48.88 vs
33.35±24.12,p=0.01) and time-dependent release formulations (38.24±18.37,p=0.04). Fur-
thermore, 28% of the patients under treatment with pH-dependent release formulations had
mucosal 5-ASA concentrations above 70 ng/mg of tissue which was the highest concentration
achieved with other formulations. Endoscopic remission was associated with significantly
higher mucosal 5-ASA concentrations than active disease in patients receiving pH-dependent
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release formulations (60.14±55.11 vs 35.66±28.44,p=0.02). The same was true for histolog-
ical assessment (67.53±56.11 vs 35.53±33.80,p<0.001). We found significantly higher
mucosal 5ASA concentrations in patients treated both orally and topically than those receiving
only oral treatment of pH-dependent release formulation (72.33±59.46 vs 51.75±48.88,p=
0.03). Conclusions: Patients with IBD show significant variability in sigmoid mucosal 5-
ASA concentration depending on the type of formulation, the highest concentration being
obtained with pH-dependent release formulations. Endoscopic and histological activity are
inversely related to mucosal concentration of 5-ASA. Higher 5ASA dosages could be therefore
justified during active disease in order to obtain better clinical results.
S1231
Predictors for Failing Thiopurine Therapy in IBD Patients; Treated At An
Academic or General District Hospital
Bindia Jharap, M. Seinen, Ronald K. Linskens, Jan Kees Kneppelhout, Chris J. Mulder,
Nanne de Boer, Ad A. van Bodegraven
Background: Several studies demonstrated that part of the IBD-patients using the immune
modulating drugs azathioprine (AZA) and 6-mercaptopurine (6-MP) fail to benefit from
thiopurines. Two 8-year interception cohorts of IBD patients with previous or present use
of thiopurines from an academic and general district hospital were assessed to determine
possible predictors for failure of thiopurine therapy. Methods: The data in this retrospective
study are based on two 8-years hospital-based interception cohorts of previous or present
thiopurine using IBD patients, treated at an academic and general district hospital. Thiopur-
ines were prescribed according to the step-up approach as recommended in current IBD
guidelines (ECCO) and were supervised by one gastroenterologist per hospital. Patients were
defined as failing thiopurine therapy in case of discontinuation of AZA or 6-MP due to
adverse events, refractoriness, both or non-compliance. Patients who continued thiopurines
due to remission of IBD were defined as non-failures. Results: At the academic hospital 281/
781 (36%) IBD patients were eligible for this study. Of these patients, 157 (56%) failed
thiopurine therapy after a median duration of 6 months (range 0-174 months) due to adverse
events (73%), refractoriness (25%) and non-compliance (2%). At the non-academic hospital,
72 out of 416 (17%) IBD patients were included. Fifty percent failed therapy after a median
duration of 1 month (range 0-64), due to adverse events (75%), refractoriness (22%) and
non-compliance (3%). No significant difference in gender, age, IBD subtype, and localization
were found between the failure and non-failure group at both hospitals. Metabolite levels
were only available in patients treated in the academic hospital. In the failures, a significant
higher 6-MMP level of 5190 pmol/10e8RBC was found compared to 1240 pmol/10e8RBC
in the non-failures. (P= 0.000) Another associated factor for failure of therapy in the described
cohorts was the 6-MMPR:6-TGN ratio. The failures had a median ratio of 34.73 compared
to 9.44 in the group that continued the use of AZA or 6-MP (P=0.000). There was no
significant difference in 6-TGN levels between failures and non-failures. (P= 0.210) Conclu-
sion: Analysis of two large 8-year interception cohorts demonstrated that more than half of
IBD patients discontinue thiopurine therapy, mostly due to the development of adverse
events. The drop-out rates were approximately the same for the academic and non-academic
hospital. Positive predictors for failing thiopurine therapy were 6-MMP levels and the ratio
between 6-MMP and 6-TGN levels.
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The TOUCH™ Program and Risk Management Plan for the Administration of
Natalizumab: Lessons and Updated Safety Results from the Use of
Natalizumab in Patients with Relapsing Multiple Sclerosis and Implications
for Potential Use in Crohn's Disease
Bruce E. Sands, Gordon Francis, Glyn Belcher, Mariska Kooijmans, Richard Kim, Frances
Lynn, Carmen Bozic, William Maier, Jean-Frédéric Colombel
Purpose: Natalizumab (TYSABRI®), the first alpha-4-integrin antagonist in late stage develop-
ment for the treatment of Crohn's disease (CD) was shown in 3 randomized, double-blind,
placebo-controlled clinical trials to be efficacious in the treatment of patients with moderately
to severely active CD. Following the occurrence of 3 cases of progressivemultifocal leukoence-
phalopathy (PML) in natalizumab-treated patients [2 in Multiple Sclerosis (MS) and 1 in
CD] and a subsequent dosing suspension, a risk management plan has been developed to
further assess natalizumab's safety. The risk management plan includes the TYSABRI Out-
reach: Unified Commitment to Health (TOUCH™) Prescribing Program for both MS and
CD; the TYSABRI Global Observation Program In Safety (TYGRIS) for MS, and the CD-
Observational Study. This abstract will show the components of the TOUCH™ risk manage-
ment program proposed to the FDA for the use of natalizumab in Crohn's disease, and will
provide updates on natalizumab utilization and safety data from the TOUCH™ Prescribing
Program and the TYGRIS study in patients receiving natalizumab for the treatment of
relapsing forms of MS. Methods: The TOUCH™ Prescribing Program for CD will be an
ongoing, mandatory safety registry in the U.S. to ensure appropriate and informed use of
natalizumab; determine the incidence of and risk factors for serious opportunistic infections
(OIs), including PML; and monitor patients for signs and symptoms of PML. The CD-
Observational Study will be a global observational study to investigate the long-term safety
of natalizumab use in CD. TYGRIS is a global observational study to investigate the long-
term safety of natalizumab use in MS. Results: As of August 23, 2007, a total of 14,010
patients receiving natalizumab for the treatment of relapsing forms of MS had been enrolled
in TOUCH™. The most current exposure and safety data from patients receiving natalizumab
worldwide will be presented. As of October 11, 2007, there have been no new reports of
confirmed cases of PML. Conclusions: Cumulative data from TOUCH™ suggest a similar
safety profile to those seen in previous clinical studies of natalizumab. Data from TOUCH™
and TYGRIS will expand our knowledge regarding the long-term safety and tolerability of
natalizumab. Preliminary data from TOUCH™ and TYGRIS continue to support the favorable
benefit-risk profile of natalizumab for patients with relapsing forms of MS. These studies
are supported by Biogen Idec, Inc., Cambridge, MA, United States and Elan Pharmaceuticals,
Inc., South San Francisco, CA, United States.
